. Author manuscript; available in PMC: 2016 Jan 31.

Published in final edited form as: Biol Blood Marrow Transplant. 2014 Nov 1;21(2):281–287. doi: 10.1016/j.bbmt.2014.10.024

Table 2.

Univariate analysis of progression-free survival between subgroups of patients with persistent indolent B-cell malignancies undergoing nonmyeloablative allogeneic transplantation.

	N	Median PFS (months)	3-Year PFS	HR (95% CI)	P
No RIT	71	19.0	44%	1.0
RIT	18	53.0	56%	0.7 (0.4–1.5)	0.36
Disease Bulk ≤5 cm	67	30.8	49%	1.0
Disease Bulk >5 cm	22	14.8	36%	1.5 (0.9–2.7)	0.15
Other Histologies	27	18.1	37%	1.0
CLL/SLL	62	23.8	50%	0.8 (0.5–1.5)	0.56
Related Donor	47	37.6	53%	1.0
Unrelated Donor	42	19.0	38%	1.1 (0.7–1.8)	0.76
Non-High-Risk Cytogenetics^a	33	53.0	61%	1.0
High-Risk Cytogenetics^a	14	19.9	43%	1.2 (0.5–2.8)	0.63

PFS, progression-free survival; HR, hazard ratio; CI, confidence interval; RIT, radioimmunotherapy; CLL/SLL, chronic lymphocytic leukemia/small lymphocytic lymphoma; MRD, matched related donor;.

“High-risk cytogenetics” were those patients with CLL/SLL that harbored deletion 11q and/or deletion 17p; all others with CLL/SLL from whom cytogenetic data were available were considered “non-high-risk”.